rituximab Injection [Rituxan]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background: Rituximab’s originator MabThera® or Rituxan® has demonstrated high efficacy in multiple sclerosis (MS). Because of…
The aims were to demonstrate pharmacokinetic (PK) similarity between DRL_RI, a proposed rituximab biosimilar, and two reference…
BACKGROUND
In patients with previously untreated chronic lymphocytic leukemia (CLL) and comorbidities, treatment with the…
Rituximab (MabThera®, Rituxan®) is an anti-CD20 monoclonal antibody that induces lysis and apoptosis of normal and malignant…
Rituximab (MabThera®, Rituxan®) is a chimeric mouse anti-human CD20 monoclonal antibody. This article reviews the use of…
Goals of workTargeted monoclonal antibodies (MoAbs) have become a promising treatment option for patients with cancer. However…
Therapeutic antibody IgG1 has two N-linked oligosaccharide chains bound to the Fc region. The oligosaccharides are of the complex…
CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody…
The objective of this multiinstitutional study was to evaluate the safety and efficacy of rituximab at standard four weekly doses…